JPWO2020205331A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020205331A5 JPWO2020205331A5 JP2021557602A JP2021557602A JPWO2020205331A5 JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5 JP 2021557602 A JP2021557602 A JP 2021557602A JP 2021557602 A JP2021557602 A JP 2021557602A JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- polypeptide sequence
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 135
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 210000004027 cells Anatomy 0.000 claims description 41
- 229920000023 polynucleotide Polymers 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 15
- 102000038129 antigens Human genes 0.000 claims description 15
- 108091007172 antigens Proteins 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 8
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 8
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drugs Drugs 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 102000002029 Claudin Human genes 0.000 claims description 6
- 108050009302 Claudin Proteins 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010017758 Gastric cancer Diseases 0.000 claims description 4
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 210000004693 NK cell Anatomy 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 4
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 4
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 200000000018 inflammatory disease Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 201000009251 multiple myeloma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 231100000486 side effect Toxicity 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 230000002463 transducing Effects 0.000 claims description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000139 costimulatory Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 6
- 210000004698 Lymphocytes Anatomy 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 230000001568 sexual Effects 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825955P | 2019-03-29 | 2019-03-29 | |
| US62/825,955 | 2019-03-29 | ||
| US201962859843P | 2019-06-11 | 2019-06-11 | |
| US62/859,843 | 2019-06-11 | ||
| US201962896758P | 2019-09-06 | 2019-09-06 | |
| US62/896,758 | 2019-09-06 | ||
| PCT/US2020/024432 WO2020205331A1 (en) | 2019-03-29 | 2020-03-24 | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527173A JP2022527173A (ja) | 2022-05-31 |
| JPWO2020205331A5 true JPWO2020205331A5 (ru) | 2022-06-29 |
Family
ID=72667032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557602A Pending JP2022527173A (ja) | 2019-03-29 | 2020-03-24 | ヒト化抗クローディン１８．２キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184126A1 (ru) |
| EP (1) | EP3947468A1 (ru) |
| JP (1) | JP2022527173A (ru) |
| KR (1) | KR20210144792A (ru) |
| CN (1) | CN113784980B (ru) |
| AU (1) | AU2020253792A1 (ru) |
| BR (1) | BR112021016673A2 (ru) |
| CA (1) | CA3132201A1 (ru) |
| IL (1) | IL286696A (ru) |
| MX (1) | MX2021011887A (ru) |
| SG (1) | SG11202109052YA (ru) |
| WO (1) | WO2020205331A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020160560A2 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| WO2022122709A1 (en) * | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CN113354739B (zh) * | 2021-01-11 | 2022-08-23 | 上海莱馥医疗科技有限公司 | 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| JP6499079B2 (ja) * | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| BR112019000327A8 (pt) * | 2016-07-08 | 2022-10-18 | Carsgen Therapeutics Co Ltd | Anticorpo para anticlaudina 18a2 e uso do mesmo |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3762031A4 (en) * | 2018-03-08 | 2021-12-22 | Phanes Therapeutics, Inc. | ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES |
-
2020
- 2020-03-24 SG SG11202109052Y patent/SG11202109052YA/en unknown
- 2020-03-24 BR BR112021016673-4A patent/BR112021016673A2/pt not_active Application Discontinuation
- 2020-03-24 US US17/593,066 patent/US20220184126A1/en active Pending
- 2020-03-24 JP JP2021557602A patent/JP2022527173A/ja active Pending
- 2020-03-24 EP EP20784482.0A patent/EP3947468A1/en not_active Withdrawn
- 2020-03-24 CA CA3132201A patent/CA3132201A1/en active Pending
- 2020-03-24 KR KR1020217034225A patent/KR20210144792A/ko unknown
- 2020-03-24 MX MX2021011887A patent/MX2021011887A/es unknown
- 2020-03-24 WO PCT/US2020/024432 patent/WO2020205331A1/en unknown
- 2020-03-24 CN CN202080026574.XA patent/CN113784980B/zh active Active
- 2020-03-24 AU AU2020253792A patent/AU2020253792A1/en not_active Abandoned
-
2021
- 2021-09-26 IL IL286696A patent/IL286696A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019173420A5 (ru) | ||
| WO2019042119A1 (zh) | 抗人cd47抗体及其用途 | |
| JP2020501531A5 (ru) | ||
| TWI564306B (zh) | 雙特異性抗體 | |
| CA2798778C (en) | Anti-human trop-2 antibody having anti-tumor activity in vivo | |
| JP2009545325A5 (ru) | ||
| JP2013502913A5 (ru) | ||
| JP2013165711A5 (ru) | ||
| JP2020528750A5 (ru) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2016526904A5 (ru) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| JP2013527761A5 (ru) | ||
| WO2012076066A1 (en) | Anti-ror1 antibodies and uses thereof | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2010509931A5 (ru) | ||
| TW200918556A (en) | Treatment of tumors using specific anti-L1 antibody | |
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| CA3043691A1 (en) | Antibody binding specifically to cd66c and use thereof | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2019512210A5 (ru) | ||
| JPWO2019224711A5 (ru) | ||
| JPWO2020205331A5 (ru) |